Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $581.78M |
| Gross Profit (TTM) | $430.34M |
| EBITDA | $97.91M |
| Operating Margin | 11.90% |
| Return on Equity | 9.43% |
| Return on Assets | 3.25% |
| Revenue/Share (TTM) | $7.29 |
| Book Value | $17.80 |
| Price-to-Book | 1.34 |
| Price-to-Sales (TTM) | 3.34 |
| EV/Revenue | 2.745 |
| EV/EBITDA | 12.84 |
| Quarterly Earnings Growth (YoY) | 58.30% |
| Quarterly Revenue Growth (YoY) | 15.10% |
| Shares Outstanding | $80.39M |
| Float | $80.00M |
| % Insiders | 0.53% |
| % Institutions | 114.95% |
Volatility is currently contracting
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel Lauren Timmins - Jefferies LLC, Research Division Mason Carrico - Stephens Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Michael Matson - Needham & Company, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2026 Financial Results Conference Call.
VCYT's stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud. CLICK HERE TO JOIN MILWAUKEE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against Veracyte (Nasdaq: VCYT).
Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it invests in its commercial teams and expands its cancer testing portfolio.
Grew total revenue to $151.8 million and testing revenue to $146.4 million , representing 15% year-over-year growth Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2026.
Two oral presentations mark Afirma's strongest podium presence in recent years, alongside eight posters Two oral presentations mark Afirma's strongest podium presence in recent years, alongside eight posters
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS Global Healthcare Conference – Palm Beach Gardens, FLFireside chat on Tuesday, November 10 at 4:15 p.m.
Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The portfolio generated a negative absolute return but outpaced the Russell Midcap Growth Index. During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. We ended our investment campaign in Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals during the quarter.
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VCYT and any ticker you trade — then tracks every position and per-strategy win rate.
